SLU-PP-332

Overview

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) — it is not a peptide. Developed in Thomas Burris's lab at Saint Louis University, it was the prototype ERR agonist studied preclinically as an "exercise mimetic." It is a research chemical, is not FDA-approved, and has no published human trials; every efficacy figure comes from rodent models.

Mechanism of Action

The estrogen-related receptors (ERRα/β/γ) are orphan nuclear receptors — they do not bind estrogen — that act as master transcriptional regulators of oxidative metabolism, driving mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and the TCA cycle, largely as partners of the PGC-1 coactivators. SLU-PP-332 activates all three isoforms with only a modest (roughly 2–4 fold) potency preference for ERRα, so it is best described as a pan-agonist rather than a selective drug. In muscle it upregulates the canonical ERR/PGC-1α aerobic gene program (PGC-1α/β, CPT1, PDK4) and shifts fiber composition toward oxidative type IIa fibers.

Research Summary

Billon et al. (ACS Chemical Biology, 2023) reported that SLU-PP-332 in sedentary mice increased treadmill endurance, enhanced slow-twitch fiber content, boosted mitochondrial biogenesis, and conferred resistance to high-fat-diet weight gain without exercise training. A follow-up (Billon et al., J Pharmacol Exp Ther, 2024) showed benefits in mouse metabolic-syndrome models. Developed at Saint Louis University (Burris/Walker/Elgendy groups). Rodent/preclinical data ONLY — no human clinical trials have been initiated. Not FDA-approved; not a peptide.

Vendors selling SLU-PP-332

Scored vendors carrying SLU-PP-332, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Prescribers who offer SLU-PP-332

2 prescribers in our directory work with SLU-PP-332, each confirmed from their own website. Peptides like SLU-PP-332 require a prescription from a licensed provider.

Reported Side Effects

• No human safety data — preclinical only
• Unknown long-term toxicity profile
• Potential off-target nuclear receptor interactions
• Unknown cardiovascular, hepatic, and reproductive risk in humans

Compare SLU-PP-332 with Others

Research References

• Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023. PMID 36988910.
• Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2023. PMID 37739806.
• Möller GM, et al. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Commun Mass Spectrom. 2026. DOI 10.1002/rcm.70039.
• SLU-PP-332. PubChem Compound Summary, CID 5338394.

Frequently asked questions

Has SLU-PP-332 been independently lab-tested?

Disclosed Labs has collected 29 Certificates of Analysis (COA) for SLU-PP-332 from 11 independent testing labs. 14 vendors have submitted material for testing. Products average 99.5% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/slu-pp-332/testing.

What is the average purity of SLU-PP-332 on the market?

Based on 29 COAs analyzed by Disclosed Labs, SLU-PP-332 products average 99.5% (±0.4%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/slu-pp-332/coas.

Which labs have tested SLU-PP-332?

Independent labs that have tested SLU-PP-332 include: ILS Labs (Grade A). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.

Where can researchers source SLU-PP-332?

2 vendors with Disclosed Labs trust grades currently list SLU-PP-332, including Glacier Aminos, Peptide Supply Co.. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/slu-pp-332.

Which prescribers offer SLU-PP-332 with a prescription?

2 prescribers in the Disclosed Labs directory work with SLU-PP-332, each confirmed from their own website. SLU-PP-332 requires a prescription from a licensed provider. Browse them at https://www.disclosedlabs.com/prescribers?peptide=SLU-PP-332.

How does SLU-PP-332 work?

The estrogen-related receptors (ERRα/β/γ) are orphan nuclear receptors — they do not bind estrogen — that act as master transcriptional regulators of oxidative metabolism, driving mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and the TCA cycle, largely as partners of the PGC-1 coactivators. SLU-PP-332 activates all three isoforms with only a modest (roughly 2–4 fold) potency preference for ERRα, so it is best described as a pan-agonist rather than a selective drug. In muscle it upregulates the canonical ERR/PGC-1α aerobic gene program (PGC-1α/β, CPT1, PDK4) and shifts fiber composition toward oxidative type IIa fibers.

What does the research say about SLU-PP-332?

Billon et al. (ACS Chemical Biology, 2023) reported that SLU-PP-332 in sedentary mice increased treadmill endurance, enhanced slow-twitch fiber content, boosted mitochondrial biogenesis, and conferred resistance to high-fat-diet weight gain without exercise training. A follow-up (Billon et al., J Pharmacol Exp Ther, 2024) showed benefits in mouse metabolic-syndrome models. Developed at Saint Louis University (Burris/Walker/Elgendy groups). Rodent/preclinical data ONLY — no human clinical trials have been initiated. Not FDA-approved; not a peptide.